PepGen Inc.
NASDAQ:PEPGBiotechnology
+$0.09 today
- Market cap
- $265.27M
- Beta
- 1.93
- P/E (TTM)
- -1.6
- EPS (TTM)
- -$1.12
Volume 3.39M
Average 1.37M
PEPG Purchases of Investments
Cash used to buy marketable securities and other investments.
PepGen Inc.NASDAQ: PEPG
Purchases of Investments · Q1 FY2026 · quarter ended Mar 2026
Purchases of investments growth accelerates
Q1 FY2026 purchases of investments of $28.46M (cash outflow) rose 323.1% year over year, ahead of the -5.7% change in trailing-twelve-month purchases of investments. Sequentially, it fell 67.4% from the prior quarter.
Context
- Purchases of investments increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +323.1% holds above the trailing-twelve-month pace of -5.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Purchases of Investments history
USD · from the cash flow
- Latest · FY2025
- (93.97M) USD
- Year-over-year change
- +35.3%
| Period | Period end | Purchases of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (93.97M) | +35.3% |
| FY2024 | 2024-12-31 | (145.17M) | -393.7% |
| FY2023 | 2023-12-31 | (29.4M) | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Purchases of Investments vs competitors
How PEPG compares with its peers on the latest reported figures
- Peers report in different currencies, so purchases of investments is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -5.7% is the 2nd highest of 7, against a peer median of -23.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $272.26M USD | -29.6% | -14.8% | — | |
| LTM Mar 2026 | $267.89M USD | -18.1% | -21.3% | 1454.6% | |
| LTM Mar 2026 | $175.25M USD | -37.4% | -21.6% | 2774.7% | |
| LTM Mar 2026 | $136.21M USD | +21.1% | +23.6% | — | |
| LTM Mar 2026 | $115.7M USD | -5.7% | — | — | |
| LTM Mar 2026 | CHF 63.3M CHF | -67.9% | -39.5% | — | |
| LTM Mar 2026 | $47.87M USD | -16.8% | -8.0% | 9118.7% | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $0 USD | — | — | — |
| Peer median (excluding PEPG) | — | -23.9% | -18.0% | 2774.7% | |
Competitors are the stored peer set for PEPG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (27.28M) | (69.1M) | (78.63M) | (89.98M) | (89.66M) |
| Depreciation & Amortization | 178K | 493K | 850K | 5.25M | 5.15M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.53M | 4.76M | 7.05M | 11.46M | 10.61M |
| Change in Working Capital | 2.77M | 4.51M | 1.95M | (5.25M) | (6.22M) |
| Accounts Receivables | (4.34M) | 4.18M | 26K | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 2.51M | (1.41M) | (369K) | 722K | (935K) |
| Other Working Capital | 4.61M | 1.73M | 2.29M | (5.97M) | (5.29M) |
| Other Non-Cash Items | 196K | 76K | (220K) | (3.86M) | (1.51M) |
| Operating Cash Flow | (22.6M) | (59.27M) | (69M) | (82.37M) | (81.64M) |
| Capital Expenditures | (500K) | (3.76M) | (2.6M) | (497K) | (264K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (29.4M) | (145.17M) | (93.97M) |
| Sales of Investments | 0 | 0 | 0 | 108M | 79M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (500K) | (3.76M) | (32M) | (37.67M) | (15.24M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 114.27M | 0 | 86.78M | 108.1M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.39M) | (2.07M) | (189K) | 1.97M | 0 |
| Financing Cash Flow | 147.66M | 112.19M | (189K) | 88.75M | 107.98M |
| Effect of Forex Changes | 33K | (316K) | 286K | (62K) | (16K) |
| Net Change in Cash | 124.59M | 48.86M | (100.9M) | (31.35M) | 11.09M |
| Free Cash Flow | (23.1M) | (63.02M) | (71.6M) | (82.87M) | (81.9M) |
PepGen Inc.
NASDAQ:PEPG
Intrinsic Alpha fair value
Locked
Current Price
$3.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.